Since a couple of months Peter Hovstadius is the new Chief Medical Officer at XNK Therapeutics, responsible for leading the medical development of the company's products. XNK operates in biotechnology and develops cell therapies (ATMP) using natural killer cells (NK cells) for cancer treatment. 

This is a new, open meeting spot for the life science sector in and around Hagastaden, and the first meeting was fully booked. The goal is to stimulate conversations and exchanges around current themes that affect many people from different perspectives.